Andrew Tsai
Stock Analyst at Jefferies
(1.31)
# 3,628
Out of 5,032 analysts
24
Total ratings
45%
Success rate
-10.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $300 | $189.99 | +57.90% | 1 | Oct 16, 2025 | |
| AKRO Akero Therapeutics | Downgrades: Hold | $75 → $56 | $53.84 | +4.01% | 1 | Oct 9, 2025 | |
| BIIB Biogen | Initiates: Buy | $190 | $143.00 | +32.87% | 1 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $22.51 | +55.49% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $33.53 | -10.53% | 1 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $70 | $54.92 | +27.46% | 1 | Jul 14, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Hold | $29 → $2.5 | $3.71 | -32.61% | 2 | May 28, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $200 | $127.94 | +56.32% | 1 | Apr 7, 2025 | |
| BEKE KE Holdings | Maintains: Overweight | $19 → $27 | $18.27 | +47.78% | 2 | Mar 19, 2025 | |
| RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $2.01 | +546.77% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $24.99 | +40.06% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $6.08 | +442.76% | 1 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $0.2 → $15 | $4.05 | +270.37% | 2 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.42 | +111.27% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $320 → $30 | $3.68 | +715.22% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $6.45 | +318.60% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $41.63 | -44.75% | 1 | Jun 1, 2020 |
Praxis Precision Medicines
Oct 16, 2025
Maintains: Buy
Price Target: $65 → $300
Current: $189.99
Upside: +57.90%
Akero Therapeutics
Oct 9, 2025
Downgrades: Hold
Price Target: $75 → $56
Current: $53.84
Upside: +4.01%
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $143.00
Upside: +32.87%
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $22.51
Upside: +55.49%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $33.53
Upside: -10.53%
BridgeBio Pharma
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $54.92
Upside: +27.46%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.71
Upside: -32.61%
Axsome Therapeutics
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $127.94
Upside: +56.32%
KE Holdings
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $18.27
Upside: +47.78%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $2.01
Upside: +546.77%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $24.99
Upside: +40.06%
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $6.08
Upside: +442.76%
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $4.05
Upside: +270.37%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.42
Upside: +111.27%
Jun 23, 2022
Downgrades: Hold
Price Target: $320 → $30
Current: $3.68
Upside: +715.22%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $6.45
Upside: +318.60%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $41.63
Upside: -44.75%